Le Lézard
Classified in: Health, Covid-19 virus
Subjects: LAW, AVO

Freedom Watch and Klayman File Class Action Suit vs. China Over COVID-19


DALLAS, March 19, 2020 /PRNewswire/ -- Today Larry Klayman, the founder of both Judicial Watch and now Freedom Watch and a former federal prosecutor, announced the filing of a class action complaint in the U.S. District Court for the Northern District of Texas (20-cv-656) for damage caused by China related to the COVID-19 virus.

The class action complaint can be found at www.freedomwatchusa.org.

PLEASE GO TO WWW.FREEDOMWATCHUSA.ORG AND JOIN AND/OR FINANCIALLY SUPPORT THIS CLASS ACTION. Contact [email protected].

Media contact: Adrienne Mazzone 561-750-9800 x2270; [email protected].

SOURCE Larry Klayman/Freedom Watch


These press releases may also interest you

at 07:45
Global Laboratory Filtration Equipment Research Report 2023-2030 - Increase in Vaccine Production, Bioburden Control in a Booming Biopharmaceutical Industry Spurs Opportunities - ResearchAndMarkets.com
The "Laboratory Filtration Equipment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Laboratory Filtration Equipment Market to Reach $3 Billion by 2030 The global market for Laboratory...

at 07:40
Global Weight Loss Drugs Markets Report 2023-2024 & 2029 - The Emergence of GLP-1 and GIP, Unmet Market Needs and Emerging Product Pipeline - ResearchAndMarkets.com
The "Global Weight Loss Drugs Market: Analysis By Product Type, By Drug Type, By Distribution Channel, By End User, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's...

at 07:35
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
Arrowhead Pharmaceuticals, Inc. today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule...

at 07:35
AbbVie Reports First-Quarter 2024 Financial Results
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and...

at 07:30
INTEGRAcare Inc. has been named as #1 Best Workplace in Healthcare in Canada & the 5th Best Workplace in Canada (across all industries) in 2024 by Great Place to Work®
During an awards ceremony to present the 2024 list of Best Workplacestm in Canada, Great Place to Work® announced the 50 Best Workplacestm in Canada with 100-999 employees....

at 07:05
Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference
At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays. Simplifying...

More news about Health...


News published on and distributed by: